Takanori Yokoyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takanori Yokoyama has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Kazuhiro Takehara
Department of Gynecology, NHO Shikoku Cancer Center, Matsuyama, Japan
9 shared publications - Akihiro Ohashi
Division of Collaborative Research and Developments, Exploratory Oncology Research and Clinical Trial Center National Cancer Center Chiba Japan
8 shared publications - Akihiro Sato
Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
8 shared publications - Chiaki Mashima
National Cancer Center 5 Division of Collaborative Research and Development, Exploratory Oncology Research and Clinical Trial Center Kashiwa, Japan
8 shared publications - Genichiro Ishii
Department of Pathology and Clinical Laboratories National Cancer Center Hospital East Kashiwa Japan
8 shared publications - Hideki Furuya
Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
8 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 1. Correlation between tumor shrinkage and number of genetic variants. Correlation analysis of tumor shrinkage versus the number of gene mutations in the specimens obtained from (a) cohort 1 and (b) cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 1. Correlation between tumor shrinkage and number of genetic variants. Correlation analysis of tumor shrinkage versus the number of gene mutations in the specimens obtained from (a) cohort 1 and (b) cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 3. Progression-free survival. Kaplan-Meier estimates of progression-free survival in (a) cohort 1 and (b) cohort 2. Disease progression was reported for 2 patients in cohort 1 and 3 patients in cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 3. Progression-free survival. Kaplan-Meier estimates of progression-free survival in (a) cohort 1 and (b) cohort 2. Disease progression was reported for 2 patients in cohort 1 and 3 patients in cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 2. Correlation between tumor shrinkage and tumor mutational burden (TMB). Correlation analysis of tumor shrinkage versus TMB in (a) cohort 1 and (b) cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 2. Correlation between tumor shrinkage and tumor mutational burden (TMB). Correlation analysis of tumor shrinkage versus TMB in (a) cohort 1 and (b) cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 5. Baseline immune-cell infiltration according to BRCA1/2 mutation status. Baseline immune-cell infiltration was compared between pretreatment biopsy samples from patients with BRCA1-mutated and BRCA2-mutated tumors using immunohistochemistry. CD3+, CD4+, CD8+, FOXP3+, CD20+, and CD204+ cells, as well as tertiary lymphoid structures (TLSs), were quantified and compared between the two groups. No statistically significant differences were observed in any of the evaluated immune-cell populations or TLSs between BRCA1-and BRCA2-mutated tumors. P values are shown for each comparison.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 5. Baseline immune-cell infiltration according to BRCA1/2 mutation status. Baseline immune-cell infiltration was compared between pretreatment biopsy samples from patients with BRCA1-mutated and BRCA2-mutated tumors using immunohistochemistry. CD3+, CD4+, CD8+, FOXP3+, CD20+, and CD204+ cells, as well as tertiary lymphoid structures (TLSs), were quantified and compared between the two groups. No statistically significant differences were observed in any of the evaluated immune-cell populations or TLSs between BRCA1-and BRCA2-mutated tumors. P values are shown for each comparison.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 1. Representativeness of Study Participants.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 1. Representativeness of Study Participants.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 4. Compartment-specific immunohistochemical analysis of immune-cell infiltration before and after treatment. Quantification of immune-cell infiltration and tertiary lymphoid structures (TLSs) in paired baseline biopsy and posttreatment surgical specimens. a, b, Tumor-compartment infiltration of CD3+, CD4+, CD8+, FOXP3+, and CD20+ lymphocytes, CD204+ macrophages, and TLSs in a, Cohort 1 and b, Cohort 2. c, d, Stromal-compartment infiltration of CD4+, CD8+, and FOXP3+ cells in c, Cohort 1 and d, Cohort 2. e, f, CD4/CD8 and FOXP3/CD8 ratios in e, the tumor compartment and f, the stromal compartment. Comparisons were performed between pretreatment baseline samples and posttreatment surgical samples.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 4. Compartment-specific immunohistochemical analysis of immune-cell infiltration before and after treatment. Quantification of immune-cell infiltration and tertiary lymphoid structures (TLSs) in paired baseline biopsy and posttreatment surgical specimens. a, b, Tumor-compartment infiltration of CD3+, CD4+, CD8+, FOXP3+, and CD20+ lymphocytes, CD204+ macrophages, and TLSs in a, Cohort 1 and b, Cohort 2. c, d, Stromal-compartment infiltration of CD4+, CD8+, and FOXP3+ cells in c, Cohort 1 and d, Cohort 2. e, f, CD4/CD8 and FOXP3/CD8 ratios in e, the tumor compartment and f, the stromal compartment. Comparisons were performed between pretreatment baseline samples and posttreatment surgical samples.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 2. Chemotherapy response scores.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 2. Chemotherapy response scores.
- 30 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4580-4591
Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Purpose: Preclinical studies suggest that poly (ADP-ribose) polymerase inhibition enhances tumor immunogenicity through stimulation of IFN genes pathway activation, providing rationale for combination with immune checkpoint inhibitors. However, clinical evidence supporting this synergy remains limited. We conducted a neoadjuvant pilot study evaluating olaparib with or without pembrolizumab in homologous recombination deficiency (HRD)–positive advanced ovarian cancer. Patients and Methods: Patients with newly diagnosed, HRD-positive International Federation of Gynecology and Obstetrics stage III to IV high-grade serous or endometrioid ovarian cancer were enrolled. HRD status was determined using the Myriad MyChoice HRD Plus test. Patients received olaparib monotherapy (300 mg twice daily for 6 weeks; cohort 1, n = 10) or olaparib plus pembrolizumab (200 mg every 3 weeks for two cycles; cohort 2, n = 20), followed by surgery and platinum-based chemotherapy. The primary endpoint was the overall response rate (ORR). Exploratory IHC and single-cell RNA sequencing analyses assessed tumor microenvironmental changes. Results: The ORR was 50% [95% confidence interval (CI), 18.7–81.3] in cohort 1 and 70% (95% CI, 45.7–88.1) in cohort 2 (P = 0.2839). In cohort 1, responses occurred only in BRCA2-mutated tumors (5/5, 100%). In cohort 2, the ORR was 84.6% (11/13) in BRCA1/2-mutated tumors and 42.9% (3/7) in non–BRCA1/2-mutated tumors. Programmed cell death ligand 1 expression, tumor mutational burden, and microsatellite instability were not associated with response. Olaparib monotherapy did not increase tumor immunogenicity, whereas the combination increased CD8+ T-cell infiltration and immune-related transcriptional changes. No unexpected toxicities were observed. Conclusions: Neoadjuvant olaparib showed measurable radiographic activity in HRD-positive advanced ovarian cancer. Pembrolizumab enhanced immune activation, but its impact on early clinical response seemed limited.
- 30 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4580-4591
Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Purpose: Preclinical studies suggest that poly (ADP-ribose) polymerase inhibition enhances tumor immunogenicity through stimulation of IFN genes pathway activation, providing rationale for combination with immune checkpoint inhibitors. However, clinical evidence supporting this synergy remains limited. We conducted a neoadjuvant pilot study evaluating olaparib with or without pembrolizumab in homologous recombination deficiency (HRD)–positive advanced ovarian cancer. Patients and Methods: Patients with newly diagnosed, HRD-positive International Federation of Gynecology and Obstetrics stage III to IV high-grade serous or endometrioid ovarian cancer were enrolled. HRD status was determined using the Myriad MyChoice HRD Plus test. Patients received olaparib monotherapy (300 mg twice daily for 6 weeks; cohort 1, n = 10) or olaparib plus pembrolizumab (200 mg every 3 weeks for two cycles; cohort 2, n = 20), followed by surgery and platinum-based chemotherapy. The primary endpoint was the overall response rate (ORR). Exploratory IHC and single-cell RNA sequencing analyses assessed tumor microenvironmental changes. Results: The ORR was 50% [95% confidence interval (CI), 18.7–81.3] in cohort 1 and 70% (95% CI, 45.7–88.1) in cohort 2 (P = 0.2839). In cohort 1, responses occurred only in BRCA2-mutated tumors (5/5, 100%). In cohort 2, the ORR was 84.6% (11/13) in BRCA1/2-mutated tumors and 42.9% (3/7) in non–BRCA1/2-mutated tumors. Programmed cell death ligand 1 expression, tumor mutational burden, and microsatellite instability were not associated with response. Olaparib monotherapy did not increase tumor immunogenicity, whereas the combination increased CD8+ T-cell infiltration and immune-related transcriptional changes. No unexpected toxicities were observed. Conclusions: Neoadjuvant olaparib showed measurable radiographic activity in HRD-positive advanced ovarian cancer. Pembrolizumab enhanced immune activation, but its impact on early clinical response seemed limited.
- Open Access
- 11 November 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (2) , 180-186
Current management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study
Background: To evaluate the current state of hereditary cancer syndrome management in patients with ovarian and endometrial cancer and to identify the barriers to uptake of genetic testing. Methods: We conducted a cross-sectional multicenter study at five regional cancer centers in Japan, including 229 patients with ovarian cancer and 454 with endometrial cancer treated between January 2021 and December 2022. We assessed the proportion of patients who received information about hereditary cancer syndromes from gynecologists, underwent genetic counseling with genetic experts, and completed genetic testing; in addition, we explored the barriers to testing uptake. Results: Among patients with ovarian cancer, 152 (66.4%) received information about hereditary cancer syndromes from their gynecologists, with 61 (26.6%) subsequently receiving genetic counseling and 58 (25.3%) undergoing genetic testing. By contrast, patients with endometrial cancer demonstrated markedly lower rates: only 76 (16.7%) received initial information, 22 (5.3%) accessed genetic counseling, and 13 (2.9%) completed genetic testing. Among patients who received information about hereditary cancer syndromes from their gynecologists, 38% with ovarian cancer and 14% with endometrial cancer underwent genetic testing. Among patients identified as high-risk for hereditary cancer syndromes through tumor profiling, 27.6% (8/29) with ovarian cancer and 70.6% (12/17) with endometrial cancer did not undergo genetic testing. Patient disinterest was the primary barrier to genetic testing among high-risk individuals. Conclusions: The barriers to uptake of genetic testing arise primarily from inadequate provider communication and patient disinterest in hereditary cancer syndromes.
- 11 November 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (2) , 180-186
Open AccessCurrent management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study
Background: To evaluate the current state of hereditary cancer syndrome management in patients with ovarian and endometrial cancer and to identify the barriers to uptake of genetic testing. Methods: We conducted a cross-sectional multicenter study at five regional cancer centers in Japan, including 229 patients with ovarian cancer and 454 with endometrial cancer treated between January 2021 and December 2022. We assessed the proportion of patients who received information about hereditary cancer syndromes from gynecologists, underwent genetic counseling with genetic experts, and completed genetic testing; in addition, we explored the barriers to testing uptake. Results: Among patients with ovarian cancer, 152 (66.4%) received information about hereditary cancer syndromes from their gynecologists, with 61 (26.6%) subsequently receiving genetic counseling and 58 (25.3%) undergoing genetic testing. By contrast, patients with endometrial cancer demonstrated markedly lower rates: only 76 (16.7%) received initial information, 22 (5.3%) accessed genetic counseling, and 13 (2.9%) completed genetic testing. Among patients who received information about hereditary cancer syndromes from their gynecologists, 38% with ovarian cancer and 14% with endometrial cancer underwent genetic testing. Among patients identified as high-risk for hereditary cancer syndromes through tumor profiling, 27.6% (8/29) with ovarian cancer and 70.6% (12/17) with endometrial cancer did not undergo genetic testing. Patient disinterest was the primary barrier to genetic testing among high-risk individuals. Conclusions: The barriers to uptake of genetic testing arise primarily from inadequate provider communication and patient disinterest in hereditary cancer syndromes.